These results suggest the possibility that alteration of the HER2-related signal with Herceptin, Lapatinib, or Rapamycin may regulate MHC class I expression on ESCC cells, leading to increased CTL sensitivity. This evidence concerns the gene ERBB2 and esophageal squamous cell carcinoma.